Document is current
Any future updates will be listed below
-
Authors
Naing, Aung https://orcid.org/0000-0002-4803-8513
Thistlethwaite, Fiona
De Vries, Elisabeth G.E.
Eskens, Ferry A.L.M.
Uboha, Nataliya
Ott, Patrick A.
LoRusso, Patricia
Garcia-Corbacho, Javier
Boni, Valentina
Bendell, Johanna
Autio, Karen A.
Randhawa, Manreet
Durm, Greg
Gil-Martin, Marta
Stroh, Mark
Hannah, Alison L.
Arkenau, Hendrik-Tobias
Spira, Alexander https://orcid.org/0000-0003-1303-0447
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03013491 at ClinicalTrials.govnct03013491 at ClinicalTrials.govDocuments that mention this clinical trial
CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
https://doi.org/10.1136/jitc-2021-002447
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
https://doi.org/10.1136/jitc-2021-002446
nct03013491 at ClinicalTrials.govDocuments that mention this clinical trial
CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
https://doi.org/10.1136/jitc-2021-002447
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
https://doi.org/10.1136/jitc-2021-002446
Documents that mention this clinical trial
CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
https://doi.org/10.1136/jitc-2021-002447
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
https://doi.org/10.1136/jitc-2021-002446
-
Funding
Funding for this research was provided by:
CytomX Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center (P30 CA008748)
- License Information
